Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)

NCT00542971 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

78

Enrollment

OTHER

Sponsor class

Conditions

AML
Acute Myeloid Leukemia
Myelodysplastic Disorders

Interventions

DRUG: Idarubicin
DRUG: Sorafenib
DRUG: Ara-C

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]